Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

Research centers across New York State are collaborating to develop cell therapies for cancer to expand progress in the emerging field of cell therapy.

Renier Brentjens, MD, PhD, invited to address Damon Runyon Foundation, New York Academy of Sciences

Roswell Park Comprehensive Cancer Center has been added to Newsweek’s list of America’s Best Cancer Hospitals for 2025.

Cancer center's Chief Strategy Officer and Chair of Thoracic Surgery joins prestigious organization

Experts from Roswell Park shared findings on these topics at the 2025 ASCO Annual Meeting.

Francisco J. Hernandez-Ilizaliturri, MD, discusses the design of an observational study investigating immunologic changes with venetoclax in CLL.

Matthew Cortese, MD, MPH, discusses the next steps for the multiomic evaluation of venetoclax activity in chronic lymphocytic leukemia.

Faculty from Roswell Park Comprehensive Cancer Center are among the experts invited to share their research findings at the 2025 ASCO Annual Meeting.

Collaborative Roswell Park/Columbia research uncovers greater risk of relapse and complications, lower survival rates.

The ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data.

Renier Brentjens, MD, PhD, discusses the current landscape of CAR T-cell agents in patients with solid tumors.

Matthew Cortese, MD, MPH, discusses the rationale for an analysis of the immunologic activity of venetoclax in patients with chronic lymphocytic leukemia.

Researchers from Roswell Park Comprehensive Cancer Center will report their latest findings to colleagues at the 2025 AACR Annual Meeting.

Eunice Wang, MD, provides an overview of currently available AML treatments and highlights the importance of mutational sequencing strategies.

Yeong “Christopher” Choi, PhD, MBA, discusses the importance of developing biomedical technologies for hematologic malignancies and other diseases.

Roswell Park Comprehensive Cancer Center achieved textbook outcomes for 90% of 150 robot-assisted minimally invasive esophagectomies from 2020-2024.

Sayan Chakraborty, PhD and team focus on targeting agrin, a protein that promotes treatment resistance/relapse.

Marco Davila, MD, PhD, discusses how a study of tumor drivers of CAR T-cell therapy resistance in LBCL may promote future biomarker investigations.

Roswell Park-led study takes a significant step toward relief without opioid.

Roswell Park Comprehensive Cancer Center surgeons will share their expertise during the 2025 annual meeting of the Society of Surgical Oncology.

Roswell Park Comprehensive Cancer Center has been recognized as a Center of Excellence for both adult and pediatric cancer treatment by Optum.

Roswell Park Comprehensive Cancer Center’s Intensive Care Unit has earned the Beacon Award for Excellence from the AACN.

Renier Brentjens, MD, PhD, details 3 reasons it’s challenging to make CAR T-cell therapies applicable for solid tumors and ways to overcome the obstacles.

Marco Davila, MD, PhD, discusses research investigating ways to combat immune escape mechanisms in LBCL treated with CD19-directed CAR T-cell therapy.

Roswell Park’s Dr Kenan Onel leads large international team that sheds light on pineoblastoma and Wilms tumor.

5 WNY organizations received funding to advance cancer prevention, early detection, and patient support from Roswell Park Comprehensive Cancer Center.

The GVHD Alliance honored Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center, as the recipient of the 2025 Lukas D. Wartman Award.

CDK2 regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs — including CDK4/6 inhibitors.

Janine Joseph, MS, MBA, discusses the effects of resistance training interventions on fatigue and pain levels in patients with multiple myeloma.

Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia.